<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856943</url>
  </required_header>
  <id_info>
    <org_study_id>SMARTCONSENT</org_study_id>
    <nct_id>NCT04856943</nct_id>
  </id_info>
  <brief_title>Effectiveness of Smartconsent in Improving Understanding of Informed Consent</brief_title>
  <acronym>SMARTCONSENT</acronym>
  <official_title>Evaluation of the Effectiveness of Smartconsent to Improve Understanding of Informed Consent in Prostate Laser Enucleation Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioaraba Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioaraba Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective of the study is to assess whether the new smartconsent tool improves&#xD;
      patients' understanding of the intervention to be performed, compared to standard practice.&#xD;
&#xD;
      A randomized clinical trial will be conducted in 50 patients who will undergo LASER PROSTATIC&#xD;
      ENUCLEATION.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Male patients aged between 50 and 70 years, belonging to the Hospital Universitario Araba who&#xD;
      are going to undergo PROSTATIC LASER ENUCLEATION, and who attend urology consultation between&#xD;
      December 2019 and December 2020, and who meet the inclusion criteria and none of the&#xD;
      exclusion criteria.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  Patients willing to receive information via tablet.&#xD;
&#xD;
        -  Patients who know how to and can read.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
      -Not applicable.&#xD;
&#xD;
      Main variable: score on the Multiple choice test questionnaire (designed specifically for&#xD;
      each type of procedure, following the recommendations proposed by Kehoe, Jerard and&#xD;
      Fathelrahman et al. and developed on the basis of the information that an informed consent&#xD;
      should provide (1, 2), with 4 response options and only one correct answer. An average score&#xD;
      will be calculated for each patient.&#xD;
&#xD;
      This test evaluates the comprehension of the information provided through the informed&#xD;
      consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score in the Multiple choice test questionnaire</measure>
    <time_frame>At the recruitment moment</time_frame>
    <description>Specifically designed for each type of procedure, following the recommendations proposed by Kehoe, Jerard and Fathelrahman et al. and developed on the basis of the information to be provided in an informed consent form, with 4 response options and only one correct answer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with the informed consent proccess</measure>
    <time_frame>At the recruitment moment</time_frame>
    <description>based on three ad hoc designed items: Each item will be scored on a lipo Likert scale with 5 response options.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to complete the informed consent form</measure>
    <time_frame>At the recruitment moment</time_frame>
    <description>Without the need for additional information from the healthcare professional.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required to complete the informed consent process (MIN).</measure>
    <time_frame>At the recruitment moment</time_frame>
    <description>The Smartphone stopwatch of the researchers participating in the study will be used for this purpose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall satisfaction with the informed consent process,</measure>
    <time_frame>At the recruitment moment</time_frame>
    <description>Through a three-item test, developed ad hoc by a group of researchers to assess satisfaction in a study with similar characteristics to ours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score in the SUS usability questionnaire</measure>
    <time_frame>At the recruitment moment</time_frame>
    <description>In the SMARTCONSENT group only</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>smartconsent group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group: : the principal investigator upon receiving the tablet enters with his/her user and password, registers his/her signature, selects the patient (anonymized), selects the intervention and then the tablet will be given to the patient and he/she will be instructed to follow the indications in order to be able to project the video and digitally sign the informed consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group: The informed consent paper document (official format) will be printed with the patient's name, signed by the physician (principal investigator) and given to the patient to read and sign.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Smartconsent application</intervention_name>
    <description>Patients asigned to smartconsent group will sign informed consent through a Tablet.</description>
    <arm_group_label>smartconsent group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>Patient asigned to control group will sing the informed consent in papel, as it is performed in clinical practice</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients willing to receive information via tablet.&#xD;
&#xD;
          -  Patients who know and can read.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not applicable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>IMANOL MERINO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioaraba Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RAQUEL COBOS</last_name>
    <phone>+34945207935</phone>
    <email>raquel.coboscampos@osakidetza.eus</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imanol Merino</name>
      <address>
        <city>Vitoria Gasteiz</city>
        <state>Alava</state>
        <zip>01003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>IMANOL MERINO</last_name>
      <email>imanolmerino80@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bioaraba Health Research Institute</name>
      <address>
        <city>Vitoria-gasteiz</city>
        <state>Alava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

